A $6 million grant awarded to Banner Sun Health Research Institute marks a significant acceleration in developing methods to identify people with Parkinson’s disease earlier and more accurately. The funding, provided by Aligning Science Across Parkinson’s (ASAP) in partnership with The Michael J. Fox Foundation for Parkinson’s Research over a three-year period, specifically targets the creation of biomarkers—measurable biological indicators that can help doctors detect Parkinson’s before or during its early stages.
This represents one of the most pressing needs in Parkinson’s care, since earlier diagnosis can change how patients manage their condition and potentially slow progression. The grant places Banner Sun Health within an expanding international research ecosystem dedicated to solving one of neurology’s most urgent diagnostic challenges. Currently, diagnosing Parkinson’s relies heavily on clinical observation and symptom assessment, methods that can miss the disease or misclassify it as other conditions, particularly in early stages when treatment interventions are most effective. The new funding enables Banner’s team, led by Nicholas Ashton, PhD, Senior Director of Banner’s Fluid Biomarker Program, to push beyond these limitations by identifying biological markers that exist in blood, cerebrospinal fluid, or other bodily substances.
Table of Contents
- How Is a $6 Million Grant Accelerating Parkinson’s Diagnosis Development?
- What Role Do Biomarkers Play in Modern Parkinson’s Research?
- How Does Banner’s Research Fit Into the Global Collaborative Network?
- What Does This Mean for Patients Seeking Earlier Diagnosis?
- What Are the Technical Challenges in Validating Parkinson’s Biomarkers?
- How Do Partnerships With Diagnostic Companies Accelerate This Work?
- What Is the Significance of Nicholas Ashton’s Leadership in This Initiative?
How Is a $6 Million Grant Accelerating Parkinson’s Diagnosis Development?
The grant provides Banner Sun Health Research Institute with resources to lead a focused research effort on biomarker discovery and validation. Biomarkers—such as specific proteins or genetic signatures in a patient’s blood—can serve as objective measures of disease presence or risk, filling the gap left by symptom-based diagnosis alone. Current diagnostic approaches depend on clinicians observing motor symptoms like tremor and rigidity or non-motor symptoms like sleep disturbance and cognitive changes, but these can take years to emerge clearly enough for confident diagnosis.
By funding specialized biomarker research, ASAP and the Michael J. Fox Foundation are investing in methods that could identify Parkinson’s disease in people who show minimal or atypical symptoms. For example, a patient experiencing only constipation, mood changes, and subtle balance issues—all early Parkinson’s indicators but easily attributed to aging or other conditions—could potentially benefit from a blood test that reveals the biological signature of Parkinson’s pathology. This acceleration is possible because the grant provides three years of dedicated funding and access to institutional resources at Banner, eliminating gaps that often slow research progress.
What Role Do Biomarkers Play in Modern Parkinson’s Research?
Biomarkers have become central to modern neurological research because they offer measurable, objective data independent of patient perception or clinician interpretation. In Parkinson’s disease, researchers focus on biomarkers related to alpha-synuclein, a protein that accumulates abnormally in the brains of people with Parkinson’s, and tau protein, another abnormal accumulation associated with neurodegeneration. Blood-based biomarkers are particularly valuable because drawing blood is non-invasive, inexpensive, and can be repeated over time to track disease progression.
However, a significant limitation is that biomarker research requires validation across diverse populations before clinical adoption. A biomarker discovered in a research cohort of 500 patients at one institution may perform differently in a broader, more diverse population. This is why the grant emphasizes Banner’s participation in the Collaborative Research Network (CRN), an international network that ensures findings are tested across 67 teams spanning 187 institutions in 24 countries. Without this multi-site validation, even promising biomarkers can fail when implemented in real clinical settings where patient populations are more heterogeneous.
How Does Banner’s Research Fit Into the Global Collaborative Network?
Banner Sun Health’s grant-funded work does not exist in isolation but instead operates within ASAP’s broader $261 million expansion of the Collaborative Research Network. This expansion created unprecedented connectivity among Parkinson’s researchers worldwide, allowing teams to share data, samples, and methods across institutional and international boundaries. Banner’s participation means their biomarker research directly feeds into and benefits from work happening at partner organizations including Beckman Coulter Diagnostics, Quanterix, Abcam, and University of Gothenburg.
This collaborative structure accelerates discovery because research teams can compare their findings against work happening simultaneously elsewhere, reducing the time required to validate results and identify confounding factors. For instance, if Banner identifies a promising blood biomarker, institutions in the CRN can immediately test whether it holds true in their patient populations, providing real-world evidence of its clinical utility. The network structure also means diagnostic tools developed through this research can move faster from laboratory validation to potential clinical deployment.
What Does This Mean for Patients Seeking Earlier Diagnosis?
The practical impact of this grant lies in the timeline for getting improved diagnostic tools into clinical use. Current blood tests for Parkinson’s biomarkers are still largely research-only, not widely available through standard medical clinics. The Banner-led initiative, backed by three years of dedicated funding and embedded in a 67-team research network, significantly shortens the pathway from laboratory discovery to clinical availability. Patients currently might wait through years of symptoms and multiple doctor visits before receiving a confident Parkinson’s diagnosis; improved biomarkers could potentially compress this timeline.
However, there is an important distinction between research funding and clinical availability. While the $6 million grant accelerates biomarker development, the subsequent steps—FDA approval for diagnostic tests, insurance reimbursement decisions, and implementation in medical practices—involve separate regulatory and logistical processes. A biomarker discovered this year might reach some clinical centers within two to three years but could take longer to become standard care at all hospitals and clinics. Patients with suspected Parkinson’s should not expect immediate access to new tests developed under this grant, but the funding represents meaningful progress toward that goal.
What Are the Technical Challenges in Validating Parkinson’s Biomarkers?
One major challenge in biomarker research is distinguishing between people who have Parkinson’s disease and those with conditions that mimic it, such as progressive supranuclear palsy, multiple system atrophy, or even essential tremor. A biomarker that works well in carefully selected research participants may perform poorly when applied to the messy reality of clinical practice, where patients present with overlapping symptoms and comorbidities. This is precisely why multi-institutional, international validation through the CRN is essential—it helps researchers understand how their biomarkers perform across different populations, genetic backgrounds, and healthcare systems.
Another limitation is that even accurate biomarkers reflect the current state of research understanding. As neuroscientists discover that Parkinson’s disease involves multiple biological pathways and subtypes, single biomarkers may become less useful than combinations of markers. The Banner team’s work, supported by the $6 million grant, will likely evolve to explore multiple biomarker panels rather than relying on any one indicator. This adds complexity to research but ultimately creates more powerful diagnostic tools.
How Do Partnerships With Diagnostic Companies Accelerate This Work?
Banner’s collaboration with companies like Beckman Coulter Diagnostics and Quanterix brings manufacturing and distribution expertise to academic research. Beckman Coulter specializes in automation and laboratory diagnostics, while Quanterix focuses on ultrasensitive protein detection—capabilities that transform laboratory discoveries into viable clinical tests.
Without industry partners, even excellent biomarker research might remain confined to academic laboratories, never reaching patients. The partnership model also addresses a practical reality: universities typically lack the infrastructure to scale diagnostic tests for nationwide or worldwide use. Industry partners can handle manufacturing, quality assurance, and distribution logistics, which are non-negotiable for any test intended for widespread clinical use.
What Is the Significance of Nicholas Ashton’s Leadership in This Initiative?
Nicholas Ashton, PhD, Senior Director of Banner’s Fluid Biomarker Program, brings a focused research program that has already produced publications on blood-based Parkinson’s biomarkers. His leadership means the Banner team enters this grant-funded work with existing expertise and published results, positioning them to move quickly from grant initiation to concrete discoveries.
Ashton’s program was selected specifically because Banner demonstrated readiness to execute sophisticated biomarker research at scale. The grant’s structure—three years, $6 million, embedded in an international research network—reflects confidence in Banner’s capability to deliver measurable progress. This is not funding for exploratory work but rather for advancing promising leads toward clinical validation.